Advanced liposome based PEGylated microgel as a novel release system for 5-fluorouracil against MCF-7 cancer cell

• Published in: European polymer journal 2021-03, Vol.146, p.110270, Article 110270
• Main Authors: Ulker, Damla, Barut, Inci, Şener, Erol, Bütün, Vural
• Format: Article
• Language: English
• Subjects: 5-FU; Biotechnology; Buffer solutions; Cancer; Cancer therapies; Drug carriers; Drug delivery; Drug delivery systems; Fibroblasts; In-vitro drug release; Liposome; Liposomes; MCF-7 breast cancer; Microgel; Microgels; Optimization; Saline solutions; Scientific imaging; Ultraviolet detectors
• ISSN: 0014-3057; 1873-1945
• DOI: 10.1016/j.eurpolymj.2021.110270

[Display omitted] •Liposome-based microgels as novel drug release system for 5-FU cancer drug molecule.•Sustained drug release of 5-FU loaded microgels being noncytotoxic on L929 cell line.•5-FU loaded lower toxic liposome-microgel has a good promising effect on MCF-7 cells.•These systems may provide new opportunities in in-vivo drug release approaches. Micro/nano-sized particles provide a control on optimization of the therapeutic index of cancer drugs. This study reports successful modification of the multi-responsive microgels based on a water-soluble 2-(N-morpholino)ethyl methacrylate (MEMA) monomer for sustained drug delivery of 5-fluorouracil (5-FU). PMEMA microgel hosting 5-FU loaded 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposome system was successfully prepared. DPPC liposome-based PMEMA microgel system was also studied in in-vitro studies as a drug carrier and controlled drug release system in phosphate buffer solution and normal saline solution. The release of 5-FU from both PMEMA microgel and liposome-based PMEMA microgel systems was analyzed using HPLC with ultraviolet spectrophotometer detector (λ 266 nm). The cytotoxic assays of liposome-based microgel and 5-FU loaded liposome-based microgel systems were investigated using L929 and MCF-7 which are mouse fibroblast cell line and breast cancer cell line, respectively. In conclusion, PEGylated PMEMA microgel and liposome-based PEGylated PMEMA microgel system provided long-time sustained drug release of 5-FU. It has been observed that the 5-FU release from PEGylated PMEMA system was faster than that of DPPC liposome-based microgel system. Additionally, 5-FU release from DPPC liposome-based microgel system was determined to be very effective on MCF-7 breast cancer cell line, which indicates great potential for further in-vivo studies.